The antiphospholipid syndrome (APS) is a prothrombotic disorder characterised by recurrent thrombotic events and pregnancy morbidity in the context of autoantibodies against phospholipid binding proteins. There is increasing evidence that these autoantibodies are associated with accelerated atherosclerosis. The presence of stenotic lesions radiologically and abnormalities of the ankle-brachial index, flow-mediated dilatation and carotid abnormalities supports this view and this clinical evidence is reviewed.
HughesGRV.The antiphospholipid syndrome: Ten years on. Lancet1993; 342: 341–344.
2.
RossR.The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature1993; 326: 801–809.
3.
RossR.Atherosclerosis - an inflammatory disease. N Eng J Med1999; 340: 115–126.
4.
HuntBJ.The endothelium in atherogenesis. Lupus2000; 9: 189–193.
5.
SteinbergD.Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem1997; 272: 20963–20966.
6.
BrownMS, GoldsteinJL.Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. A Rev Biochem1983; 52: 223–261.
7.
HenriksenT, MahoneyEM, SteinburgD.Enhanced macrophage degradation of low density lipoproteins previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA1981; 78: 6499–6503.
8.
HenriksenT, MahoneyEM, SteinburgD.Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis1983; 3: 149–159.
9.
VaaralaO, ManttariM, ManninenVAnti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation1995; 91: 23–27.
10.
CerveraR.Coronary and valvular syndromes and antiphospholipid antibodies. Thrombosis Research2004; 114: 501–507.
11.
SletnesKE, SmithP, AbdelnoorM, ArnesenH, WisloffF.Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction and non-haemorrhagic stroke. Lancet1992; 339: 451–453.
12.
SimantovR, LaSalaJM, LoSKActivation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest1995; 96: 2211–2219.
13.
Del PapaN, GuidaliL, SalaAEndothelial cells as targets for antiphospholipid antibodies. Arthritis Rheum1997; 40: 551–561.
14.
PierangeliSS, Colden-StanfieldM, LiuX, BarkerJH, AndersonGL, HarrisEN.Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation1999; 99: 1997–2002.
15.
HasunumaY, MatsuraE, MakitaZ, KatahiraT, NishiS, KoikeT.Involvement of ß2 glycoprotein I and anticardiolipin antibodies in oxidatively modified low density lipoprotein uptake by macrophages. Clin Exp Immunol1997; 107: 569–574.
16.
VaaralaO, AlfthanG, JauhiainenM, Leirisalo-RepoM, AhoKND, PalosuoT.Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet1993; 2: 923–925.
17.
MaggieE, PeraniG, FalaschiFAutoantibodies against oxidized LDL in patients with coronary disease. Presse Med1994; 23: 1158–1162.
18.
VaaralaO.Antibodies to oxidized LDL. Lupus2000; 9: 202–205.
19.
RoubeyRAS.Immunology of antiphospholipid syndrome. Arthritis Rheum1996; 39: 1444–1456.
20.
BlankM, ShoenfeldY, CabillySPrevention of experimental antiphospholipid syndrome and endothelial cell activation by peptides. Proc Natl Acad Sci1999; 96: 5164–5168.
21.
GeorgeJ, HaratsD, GilburdBImmunolocalisation of β2-glycoprotein I (Apolipoprotein H) to human atherosclerotic plaques. Circulation1999; 99: 2227–2230.
22.
MatsuuraE, LopezLR.Are oxidized LDL/β2-glycoprotein I complexes pathogenic antigens in autoimmune mediated atherosclerosis?Clin Dev Immunol2004; 11: 103–111.
23.
GeorgeJ, AfekA, GilburdBInduction of early atherosclerosis in LDL deficient mice immunized with β2-glycoprotein I. Circulation1998; 98: 1108–1115.
24.
MedinaG, CasaosD, JaraLJIncreased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis2003; 62: 607–610.
25.
AmesPR, MargaritaA, Delgado AlvesJAnticardiolipin antibody titre and plasma homocysteine level independently predict intimal media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus2002; 11: 208–214.
26.
AmesPR, MargaritaA, SokollKBPremature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis2005; 64: 315–317.
27.
CharakidaM, HalcoxJP, SangleSPreclinical atherosclerotic phenotype in patients with primary antiphospholipid syndrome. Rheumatology2006 (abstract).
28.
BaronM, D'CruzD, KhamashtaMA, HughesGRV.Prevalence of abnormal ankle-brachial index in primary antiphospholipid syndrome. Ann Rheum Dis2005; 64: 144–146.
29.
ChristodoulouC, ZainM, BertolacciniMLThe prevalence of an abnormal ankle-brachial index in antiphospholipid syndrome patients with pregnancy loss but without thrombosis: a controlled study. Ann Rheum Dis2000; 65: 683–684.
30.
SangleSR, D'CruzDP, JanWRenal artery stenosis in antiphospholipid syndrome and hypertension. Ann Rheum Dis2003; 62: 999–1002.
Sipek-DornicarA, HojnikM, BozicB, VizjakA, RozmanB, FerlugaD.Clinical presentation and vascular histopathology in autopsied patients with systemic lupus erythematosus and anticardiolipin antibodies. Clin & Exper Rheum2002; 20: 335–342.
33.
KojimaE, NaitoK, IwaiM, HiroseY, IsobeK, TakanoK.Antiphospholipid syndrome complicated by thrombosis of the superior mesenteric artery, co-existence of smooth muscle hyperplasia. Intern Med1997; 36: 528–531.
34.
MeroniPL, BorghiMO, RaschiEInflammatory response and the endothelium. Thrombosis Research2004; 114: 329–334.
35.
PetriM.Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus1996; 5(Suppl 1): S16–S22.
36.
RomanMJ, ShankerBA, DavisA, LockshinMD, SammaritanoLPrevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med2003; 349: 2399–2406.
37.
FerraraDE.Inhibition of thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum2003: 48; 3272–3279.
38.
CuadradoMJ, BuendiaP, AguirreAEffect of fluvastatin on monocyte tissue factor expression in primary antiphospholipid syndrome. Preliminary results of an in vivo study. Arthritis Rheum2005; 52: S263 (613).
39.
AllisonAC, EuguiEM.Mycophenolate mofetil and it's mechanism of action. Immunopharm2000; 47: 85–118.
40.
RomeroF, Rodriguez-IturbeB, PonsHMycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis2000; 152: 127–133.
41.
GreensteinSM, SunS, CalderonTMMycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit. J Vasc Res2000; 91: 123–129.
42.
KobashigawaJ, MillerL, RenlundDA randomized activecontrolled trial of mycophenolate mofetil in heart transplant recipients. Transplantation1998; 66: 507–515.
43.
GeorgeJ, ShoenfeldY.The antiphospholipid ‘Hughes syndrome’ syndrome: a cross roads of autoimmunity and atherosclerosis. Lupus1997; 6: 559–560.
